Abstract:Abstract Background and Aims Chronic kidney disease is a common disease. Most chronic kidney diseases evolve from primary glomerulonephritis. Proteinuria is an independent risk factor for the progression of chronic kidney disease. The general consensus is that therapy administered to decrease proteinuria should include steroids and/or immunosuppressants, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. However, the side effects of, and adverse reactions to, these agents reduce the benefits to patients. Therefore, additional effective drugs to decrease proteinuria are urgently needed. Shenyankangfu tablets (SYKFT) have been a widely applied Chinese patent medicine for many years to decrease proteinuria. However, there is a lack of research-derived data regarding the clinical use. Therefore, we designed the present trial to compare the efficacy and safety of SYKFT versus losartan potassium for control of proteinuria in patients with primary glomerulonephritis. Method This was a multicenter, prospective, double-blind, double-dummy, randomized controlled clinical trial. Primary glomerulonephritis patients aged 18 to 70 years, blood pressure ≤140/90 mmHg, estimated glomerular filtration rate ≥45 mL/min/1.73 m2, 24-hour proteinuria level of 0.5 to 3.0 g, were recruited in 41 hospitals across 19 provinces in China and were randomly divided into the following groups at a 1:1:1:1:1 ratio: SYKFT group, losartan potassium 50 mg group, losartan potassium 100 mg group, SYKFT plus losartan potassium 50 mg group, and SYKFT plus losartan potassium 100 mg group. All groups were followed up for 48 weeks; follow-up visits were performed, at weeks 0, 4, 8, 12, 24, 36, and 48. The primary efficacy outcome was the post-treatment change in the 24-hour proteinuria level, and the secondary efficacy outcomes was the post-treatment changes in the serum creatinine level, estimated glomerular filtration rate (eGFR), traditional Chinese medicine (TCM) syndrome score, and serum albumin level. The protocol was approved by the Ethics Committee of each participating center. This trial was registered at the clinicaltrials.gov (NCT02063100). Results A total of 720 participants were enrolled and 673 patients were included in the analysis. The difference in the urine protein reduction among different groups was statistically significant (Z=20.084, P=0.001). The urine protein reduction in the SYKFT group [-150.000 (-692.500, 153.000) mg/d], more than that in the losartan potassium 50mg alone group [-80.000 (-420.000, 295.250) mg/d, Z=-2.015, P=0.044], was not less than that in the losartan potassium 100mg group [-260.000 (-623.900, 84.000) mg/d, Z=-0.339, P=0.734]. The urine protein reduction in the SYKFT plus losartan potassium 50mg group [-269.150 (-755.000, 159.085) mg/d] was more than that in the losartan potassium 50mg alone group [Z=-2.582, P=0.010]. The urine protein reduction in the SYKFT plus losartan potassium 100mg group [-388.000 (-743.500, -10.000) mg/d] was more than that in the losartan potassium 100mg alone group [Z=-1.999, P=0.046]. The changes in serum creatinine, eGFR, and serum albumin from the baseline were not statistically significant among different groups (P all >0.05). The change in TCM syndrome scores between the patients who took SYKFT and who did not take SYKFT was statistically significant (P=0.003). Conclusion SYKFT can decrease the proteinuria of primary glomerulonephritis patients with minor- to moderate-range proteinuria. SYKFT plus losartan potassium therapy can decrease proteinuria to a relatively large extent compared with losartan potassium therapy alone. And SYKFT can also improve the TCM syndrome scores of the patients.

Clinical efficacy and safety of losartan potassium combined with yishenhuashi in the treatment of chronic glomerulonephritis

Clinical Observation of Yishen Huashi Granula Plus Lotensin in Treatment of Chronic Glomerulonephritis

Meta-analysis of the effectiveness and safety of Shenyankangfu tablets combined with losartan potassium in the treatment of chronic glomerulonephritis

P0394EFFICACY AND SAFETY OF A CHINESE PATENT MEDICINE-SHENYANKANGFU TABLETS FOR PRIMARY GLOMERULONEPHRITIS:A RANDOMISED CONTROLLED TRIAL

Clinical Observation of Tea Polyphenol Tablet on Chronic Glomerulonephritis

Efficacy and safety of Shenyankangfu Tablet, a Chinese patent medicine, for primary glomerulonephritis: A multicenter randomized controlled trial

Clinical Analysis of double dosage Losartan on renal hypertension patients with chronic glomerulonephritis

Effect of Jianping Yishen Xiezhuo decoction combined with western medicine on immune function and microinflammatory state in the treatment of patients with chronic renal failure

[Treatment of chronic primary glomerulopathy patients of Shen deficiency and dampness heat syndrome by yishen qingli granule combined low-dose Tripterygium wilfordii multiglycoside tablet: a clinical efficacy observation]

The clinical efficacy of Wenshen-Jiangzhuo-Tongluo in the treatment of 60 cases of patients with early and middle chronic renal failure

Clinical research on treating IgA nephropathy by irbesartan combined with Shenyan Kangfu tablets

Clinical Nephrology - IgA Nephropathy, Lupus Nephritis, Vasculitis

Clinical study of traditional Chinese medicine Shanhong Mixture in the treatment of chronic glomerulonephritis

Effect of Combination of Benazepril,Salvia Miltiorrhiza and Spironolactone on Glomerular Filtration Rate in Patients with Diabetic Nephropathy

Effect of angiotensin converting enzyme inhibitor and angiotensin Ⅱ receptor blocker on renin-angiotensin system in patients with chronic kidney disease

Treatment of Massive Proteinuria in Kidney Transplant Recipients by Losartan

Effects of Losartan on Tubulointerstitial Hypoxia Inducible Factors and Connective Tissue Growth Factors in Progressive Nephritis Model Rats

Study on Effect of Benazepril and Telmisartan in the Treatment of Patients with Patients with Early Diabetic Nephropathy

Therapeutic Efficacy of Astragalus in Patients with Chronic Glomerulonephritis

Yi-Shen-Hua-Shi regulates intestinal microbiota dysbiosis and protects against proteinuria in patients with chronic kidney disease: a randomized controlled study

Clinical Observation on Kangxianling Formula for 110 Cases of Chronic Kidney Disease of Stage Ⅲ